Nasdaq

Bio-Techne Announces Publication Of ExoDx Prostate Test Study In Patients With Prior Negative Prostate Biopsy

MINNEAPOLIS, Sept. 23, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in BMC Urology, entitled A urine-based Exosomal gene expression test ...
Business Insider

Bio-Techne Announces Publication of ExoDx™ Prostate (IntelliScore) EPI Test Clinical Utility Study

MINNEAPOLIS, May 7, 2020 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced a major publication in the Journal of Prostate Cancer and Prostatic Diseases entitled, Clinical Utility of ...
Nasdaq

BIO-TECHNE ANNOUNCES PUBLICATION OF NEW DATA DEMONSTRATING EXODX PROSTATE TEST CORRELATION WITH POST-PROSTATECTOMY PATHOLOGY OUTCOMES

MINNEAPOLIS, Feb. 14, 2022 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced an important publication in World Journal of Urology, entitled Pre–diagnosis urine exosomal RNA (ExoDx ...
abc27

ExoDx PROSTATE TEST GRANTED EXPANDED COVERAGE BY MEDICARE

Medicare contractor National Government Services finalizes local coverage determination for biomarker testing related to prostate cancer to include repeat biopsies and yearly testing Prostate cancer ...
Business Insider

CareFirst BlueCross BlueShield and Exosome Diagnostics Announce Evidence Development Collaboration for Molecular Diagnostic TestsProgram designed to accelerate access to ExoDx ...

August 24, 2017 - Baltimore, Md. and Boston, Ma., Aug. 24, 2017 (GLOBE NEWSWIRE) -- CareFirst BlueCross BlueShield (CareFirst) and Exosome Diagnostics, Inc. (ExoDx) announced today that they have ...
Yahoo Finance

Bio-Techne Announces Exosome Diagnostics Divestiture

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...